ClinicalTrials.gg
CompletedNCT00216489Updated Apr 26, 2010

A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)

A Phase 4 interventional study of rabeprazole sodium in Gastroesophageal Reflux and Heartburn, sponsored by Janssen Cilag Pharmaceutica S.A.C.I., Greece. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-04-26.

Sponsored by Janssen Cilag Pharmaceutica S.A.C.I., Greece (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
191
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.

Enrollment
16th of 39
191 · median 100
Started
2003
the only one that year
Phase 4
8 of 40
none open now
Registered
5th of 40
by date

Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 16th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2003, is one of 8 in phase 4, and was the 5th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →

About rabeprazole

Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing rabeprazole in Gastroesophageal Reflux as a file.
02

Study summary

The purpose of the study is to confirm the safety and effectiveness of rabeprazole in the treatment of patients with erosive or ulcerative gastroesophageal reflux disease (GERD) in routine primary health care.

Read the detailed description

Gastroesophageal reflux can result in mild to severe symptoms in some persons. Heartburn, a burning sensation or discomfort rising behind the breastbone, is a common symptom. Gastroesophageal reflux disease (GERD) can be described as a condition with clearly identified clinical symptoms or the change in tissue structure that results from the reflux of contents from the stomach or small intestine into the esophagus. This is a study to confirm the safety and effectiveness of rabeprazole in the treatment of patients with GERD in routine primary health care. The study has two phases. Patients will receive treatment with rabeprazole tablets once daily for 8 weeks. In the second phase, patients will be monitored by their physician for a follow up period to end of study (12 months). Safety assessments include the incidence of adverse events throughout the treatment and follow up phases, and physical examination and laboratory tests at end of treatment and after 4 months. Assessments of effectiveness include the degree of relief of symptoms at beginning and end of treatment and at specific intervals during follow up. The study hypothesis is that rabeprazole is well-tolerated with long term treatment of patients with GERD in routine primary health care. Rabeprazole tablet (20 milligrams[mg]) once daily in the morning for 8 weeks. Dose may be increased to 2 tablets daily (40 mg maximum) at investigator's discretion.

03

Conditions studied

  • Gastroesophageal Reflux
  • Heartburn

Keywords

  • gastroesophageal reflux
  • heartburn
  • rabeprazole
  • GERD
  • anti-ulcer agents
  • proton pump inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with symptoms of erosive or ulcerative gastroesophageal reflux disease (GERD) during at least a period of 3 months prior to study initiation and symptoms of GERD for at least 3 days per week within the 2 weeks prior to study initiation. The symptoms of erosive or ulcerative gastroesophageal reflux disease includes the following: heartburn, aching behind the breastbone, a need for antacids, and difficulty in swallowing. Patients with evidence by endoscopy of erosive or ulcerative gastroesophageal reflux disease with no Barret-type tissue transformation.

Exclusion criteria

Exclusion Criteria:

  • No narrowing or inflammation of the esophagus
  • no known gastro-duodenal ulcer
  • no infections (other than H. Pylori), inflammations or hemorrhage of the stomach, small or large intestine
  • no prior surgery of the stomach or intestine
  • no known history of primary kinetic disorders of the esophagus, other than GERD
  • no history of enlarged veins of the esophagus or stomach
  • no pregnant or nursing females, or those lacking adequate .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
191 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events throughout treatment (8 weeks) and follow up (12 months)

Secondary outcomes

  1. Severity of symptoms at baseline and specified intervals during treatment and follow up, rated from "no problem" to "very severe problem"; physical examination and laboratory tests at end of treatment and after 4 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 22, 2005
Start
Mar 2003
CompletionActual
Nov 2005
Last update
Apr 26, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00216489
First posted
Sep 22, 2005
Start date
Mar 2003
Completion
Nov 2005
Last update
Apr 26, 2010

Study contacts

Janssen-Cilag Pharmaceutica S.A.C.I. Clinical Trial
study director · Janssen-Cilag Pharmaceutica S.A.C.I.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion